6th TPD and Induced Proximity Summit Europe

The 6th TPD and Induced Proximity Summit Europe is the only European forum dedicated exclusively to proximity-based drug discovery. From PROTACs and molecular glues to stabilizers and extracellular degraders, this summit showcases the full spectrum of therapeutic innovation across oncology, neurodegeneration, immunology, and rare diseases. Held in London in March 2026, the event brings together more than 80 CxOs, directors, senior scientists and investors to accelerate proximity therapeutics from discovery to clinic.

 

Europe is experiencing a surge in strategic investment and innovation, including Sanofi’s acquisition of Blueprint Medicines for  billion and Merck’s  billion purchase of SpringWorks Therapeutics. As the region pivots toward non-oncology indications and novel mechanisms, drug developers face challenges in rational design, oral bioavailability, PK and PD modelling, and clinical translation. This summit addresses those challenges with insights from leading companies such as GSK, Abbvie, Amphista, Autotac Bio, PhoreMost, Laigo Bio, and Foghorn Therapeutics. Attendees will gain access to first-in-human data, biology-first strategies, and novel degradation platforms that are redefining the druggable proteome.

 

Whether you are advancing early discovery or preparing clinical candidates, this is your essential opportunity to connect with Europe's most innovative biopharma teams and stay ahead in the evolving induced proximity landscape.